
Transforming eyecare with AI
AI in eyecare will play an important role in alleviating future public health challenges, says Dr Pearse Keane, Moorfields consultant and professor of artificial medical intelligence at UCL

AI in eyecare will play an important role in alleviating future public health challenges, says Dr Pearse Keane, Moorfields consultant and professor of artificial medical intelligence at UCL

Using a mindfulness-based breathing technique reduces intraocular pressure (IOP) and serum cortisol levels and improves autonomic dysfunction in patients with primary open-angle glaucoma (POAG), a stu

Tiny solar panels placed at the back of the eye could help patients recover from sight loss, a University of Surrey study has found. For most sufferers of age-related macular degeneration ther

Hosted at Auckland’s Cordis Hotel, the Royal Australian and New Zealand College of Ophthalmologists’ (RANZCO’s) New Zealand Annual Scientific Meeting is booked for 16-18 May 2024.

Glaucoma poses a significant threat to vision if left untreated. With 112 million people estimated to be affected by 20401, it ranks globally as the second leading cause of blindness2, emphasising the essential role of adherence to ocular hypertensive medications in preventing irreversible vision lo

A new shared-care e-Learning course for implantable collamer lenses (ICL) for optometrists in New Zealand and Australia has been unveiled by Device Technologies in collaboration with Staar Surgical.

International consortium BIENCO has been awarded AU$35 million to further the development of bioengineered eye tissue to treat corneal blindness.

Located in the heart of Auckland’s CBD, optometrist trio Dr Vivienne Zhang, Charisse Kuo and Gina Partridge have opened New Zealand’s first clinic specialising in myopia management: the Auckland Myopia Clinic.

Aspen Pharmacare’s Eikance 0.01% atropine drops have been approved by Medsafe and will be available via prescription from pharmacies in New Zealand from the end of June 2024.

A US study found an artificial intelligence (AI) system matched, or in some cases outperformed, experienced ophthalmologists in their diagnoses and proposed treatments for glaucoma and retinal disease

Early data from the phase 2 trial of gene therapy Ixo-vec (ixoberogene soroparvovec, formerly ADVM-022), demonstrated potential best-in-class clinical activity in treatment burden reduction for “hard

Harmful gut bacteria found in the retinas of mice with certain inherited retinal diseases (IRDs) were treated with antimicrobials, preventing vision loss, reported the authors of a UK-Chinese study.